Glögl M., Friedrich N., Cerutti G. et al. (2023). Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization. Nat Struct Mol Biol. doi.org/10.1038/s41594-023-01062-z
Feraoun Y, Palgen JL, Joly C, Tchitchek N, Marcos-Lopez E, Dereuddre-Bosquet N, et al. (2022). The route of Vaccine Administration determines whether blood neutrophils undergo long-term phenotypic modifications. Frontiers in Immunology. 2022;12. doi.org/10.3389/fimmu.2021.784813.
Malatinkova E, Thomas J, De Spiegelaere W, Rutsaert S, Geretti AM, Pollakis G, et al. (2021). Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising Human Alu Repeat Sequences. Life. 2021; 11(12):1410. doi.org/10.3390/life11121410.
Highton AJ, Diercks B-P, Möckl F, Martrus G, Sauter J, Schmidt AH, et al. (2020). High metabolic function and resilience of NKG2A-educated NK Cells. Frontiers in Immunology. 2020;11. doi.org/10.3389/fimmu.2020.559576.
Hauser A, Carnell G, Held K, Sulbaran G, Tischbierek N, Rogers L, et al. (2021). Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses. Vaccines. 2021; 9(7):750. doi.org/10.3390/vaccines9070750.
Friedrich N, Stiegeler E, Glögl M, Lemmin T, Hansen S, Kadelka C, et al. (2021). Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization. Nat Commun 12, 6705. doi.org/10.1038/s41467-021-27075-0.
Lungu C, Banga R, Gruters R, & Procopio AF. (2021). Inducible HIV-1 Reservoir Quantification: Clinical Relevance, Applications and Advancements of TILDA. Front. Microbiol. 2021 Jun 15. doi.org/10.3389/fmicb.2021.6866900.
Peterhoff D, Thalhauser S, Sobczak JM, Mohsen MO, Voigt C, Seifert N, et al. (2021). Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery. Vaccines, 9(6):642. 2021 Jun 11. doi.org/10.3390/vaccines9060642.
Rao S, Lungu C, Crespo R, Steijaert TH, Gorska A, Palstra, RJ, et al. (2021). Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir. Nature communications, 12(1), 2475. 2021 Apr 30. doi.org/10.1038/s41467-021-22608-z.
Lungu C, Procopio FA, Overmars RJ, Beerkens R, Voermans J, Rao S, et al. (2020). Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA. Viruses, 12(9), 973. 2020 Sep 02. doi.org/10.3390/v12090973.
Joachim A, Ahmed M, Pollakis G, Rogers L, Hoffmann VS, Munseri P, et al. (2020). Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost. Frontiers in immunology, 11, 719. 2020 Apr 28. doi.org/10.3389/fimmu.2020.00719.
Palgen JL, Tchitchek N, Rodriguez-Pozo A, Jouhault Q, Abdelhouahab, Dereuddre-Bosquet N, et al. (2020). Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations. npj Vaccines 5, 24. doi.org/10.1038/s41541-020-0175-8.
Su B, Dispinseri S, Iannone V, Zhang T, Wu H, Carapito R, et al. (2019). Update on FC-mediated antibody functions against HIV-1 beyond neutralization. Frontiers in Immunology. 2019;10. doi.org/10.3389/fimmu.2019.02968.
Couto E, Diaz-Brito V, Mothe B, Guardo AC, Fernandez I, Ugarte A, et al. (2019). Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B. Vaccines. 2019; 7(4):178. doi.org/10.3390/vaccines7040178.
Wilmschen S, Schmitz JE, Kimpel J. (2019). Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV. Vaccines. 2019; 7(3):119. doi.org/10.3390/vaccines7030119.
Bresk CA, Hofer T, Wilmschen S, Krismer M, Beierfuß A, Effantin G, et al. (2019). Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector. Viruses. 2019; 11(2):159. doi.org/10.3390/v11020159.
Perdiguero B, Gómez CE, García-Arriaza J, Sánchez-Corzo C, Sorzano CÓS, Wilmschen S, et al. (2019). Heterologous combination of VSV-gp and NYVAC vectors expressing HIV-1 trimeric GP145 env as vaccination strategy to induce balanced B and T cell immune responses. Frontiers in Immunology. 2019;10. doi.org/10.3389/fimmu.2019.02941.
Pérez P, Marín MQ, Lázaro-Frías A, Sorzano CÓS, Di Pilato M, Gómez CE, Esteban M, García-Arriaza J. (2019). An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design. Vaccines. 2019; 7(4):208. doi.org/10.3390/vaccines7040208.
Perdiguero B, Sánchez-Corzo C, Sorzano COS, Saiz L, Mediavilla P, Esteban M, Gómez CE. (2019). A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses. Viruses. 2019; 11(2):160. doi.org/10.3390/v11020160.
Raman SC, Mejias-Pérez E, Gomez CE, García-Arriaza J, Perdiguero B, Vijayan A, et al. (2019). The envelope-based fusion antigen gp120c14k forming hexamer-like structures triggers T cell and neutralizing antibody responses against HIV-1. Frontiers in Immunology, 10. doi.org/10.3389/fimmu.2019.02793.
Wittner M, Schlicker V, Libera J, Bockmann JH, Horvatits T, Seiz O, et al. (2019) Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis. PLOS ONE 14(7): e0220008. doi.org/10.1371/journal.pone.0220008.
Moore C, Stöhr W, Crook AM, Richert L, Leliévre JD, Pantaleo G, et al. (2019). Multi-arm multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions. Lancet HIV, 6(5):e334-e340. 2019 May 01. doi.org/10.1016/S2352-3018(19)30082-7.
Nadai Y, Held K, Joseph S, Ahmed M, Hoffmann VS, Peterhoff D, et al. (2019). Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence. Frontiers in immunology, 10, 717. 2019 Apr 24. doi.org/10.3389/fimmu.2019.00717.
Jean-Louis P, Tchitchek N, Huot N, Elhmouzi-Younes J, Lefebvre C, Rosenbaum P, (2019). NK cell immune responses differ after prime and boost vaccination. Journal of Leukocyte Biology, Volume 105, Issue 5, May 2019, Pages 1055–1073. doi.org/10.1002/JLB.4A1018-391RR.
Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, et al. (2018). Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. PLoS ONE 13(12): e0208345. doi.org/10.1371/journal.pone.0208345.
Human Gene Therapy.Sep 2018.1011-1028. doi.org/10.1089/hum.2018.075.
Pfeifer C, Highton AJ, Peine S, Sauter J, Schmidt AH, Bunders MJ, et al. (2018). Natural killer cell education is associated with a distinct glycolytic profile. Frontiers in Immunology. 2018;9. doi.org/10.3389/fimmu.2018.03020.
Wagner R, Asbach B. (2018). Dürfen wir noch auf eine HIV-Impfung hoffen? MMW - Fortschritte der Medizin 160 (Suppl 2), 24–27. doi.org/10.1007/s15006-018-0649-z.
Palgen JL, Tchitchek N, Elhmouzi-Younes J, Delandre S, Namet I, Rosenbaum P, et al. (2018). Prime and Boost Vaccination Elicit a Distinct Innate Myeloid Cell Immune Response. Sci Rep 8, 3087. doi.org/10.1038/s41598-018-21222-2.
Parsons MS, Le Grand R, Kent SJ. (2018). Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. Viruses. 2018; 10(6):333. doi.org/10.3390/v10060333.
Kratochvil S, McKay PF, Chung AW, Kent SJ, Gilmour J, Shattock RJ. Immunoglobulin G1 allotype influences antibody subclass distribution in response to HIV GP140 vaccination. Frontiers in Immunology. 2017;8. doi.org/10.3389/fimmu.2017.01883.
F. (2017). New challenges in therapeutic vaccines against HIV infection. Expert Review of Vaccines, 16:6, 587-600. doi.org/10.1080/14760584.2017.1322513.
Mayr LM, Su B, Moog C. (2017). Non-neutralizing antibodies directed against HIV and their functions. Frontiers in Immunology. 2017;8. doi.org/10.3389/fimmu.2017.01590.
Kratochvil S, McKay PF, Kopycinski JT, Bishop C, Hayes PJ, Muir L, et al. (2017). A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Frontiers in immunology, 8, 595. 2017 May 24. doi.org/10.3389/fimmu.2017.00595/fimmu.2017.00595.
Peterhoff D, Wagner R. (2017). Guiding the long way to broad HIV neutralization. Current Opinion in HIV and AIDS, 12(3):p 257-264, May 2017. doi.org/10.1097/COH.0000000000000356.
Wagner R. (2017). Effective HIV vaccine: narrow path to broadly neutralizing antibodies? Current Opinion in HIV and AIDS, 12(3):p 191-194, May 2017. doi.org/10.1097/COH.0000000000000371.
Asbach B, Wagner R. (2017). Particle-based delivery of the HIV envelope protein. Current Opinion in HIV and AIDS, 12(3):p 265-271, May 2017. doi.org/10.1097/COH.0000000000000366.
Medina-Ramírez M, Sanders RW, Sattentau QJ. (2017). Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Current Opinion in HIV and AIDS, 12(3):p 241-249, May 2017. doi.org/10.1097/COH.0000000000000363.
